SEARCH:   Advanced

Blood, 1 December 2005, Vol. 106, No. 12, pp. 4002-4008. Prepublished online as a Blood First Edition Paper on August 16, 2005; DOI 10.1182/blood-2005-05-1937. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-05-1937v1 106/12/4002    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Burroughs, L. Articles by Storb, R. Search for Related Content PubMed PubMed Citation Articles by Burroughs, L. Articles by Storb, R. Related Collections Hematopoiesis and Stem Cells Transplantation Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model Lauri Burroughs, Marco Mielcarek, Marie-Térèse Little, Gary Bridger, Ron MacFarland, Simon Fricker, Jean Labrecque, Brenda M. Sandmaier, and Rainer Storb From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle WA; the Department of Pediatrics, University of Washington, Seattle, WA; the Department of Medicine, University of Washington, Seattle, WA; and AnorMED, Langley, BC. Peripheral-blood mononuclear cells (PBMCs) mobilized with AMD3100, a CXCR4 antagonist, combined with granulocyte colony-stimulating factor (G-CSF) have reconstituted autologous hematopoiesis in cancer patients following myeloablative conditioning. The engraftment potential of PBMCs mobilized with AMD3100 alone, however, has remained unproven. We therefore studied AMD3100-mobilized PBMCs in a canine model. Four dogs received 920 cGy total body irradiation (TBI) before infusion of autologous AMD3100-mobilized PBMCs (median CD34 cell count, 3.9 x 106/kg). Neutrophil (> 0.5 x 109/L [500/µL]) and platelet (> 20 x/109/L [> 20 000/µL]) recoveries occurred at medians of 9 (range, 7-10) days and 25 (range, 23-38) days, respectively, after TBI, and all dogs had normal marrow function at 1 year after transplantation. To evaluate the long-term engraftment potential of AMD3100-mobilized PBMCs, 5 dogs were given 920 cGy TBI followed by infusion of AMD3100-mobilized PBMCs (median CD34 cell dose, 4.7 x 106/kg) from their dog leukocyte antigen (DLA)-identical littermates. Neutrophil and platelet recoveries occurred at medians of 8 (range, 8-10) days and 26 (range, 26-37) days, respectively, after TBI. With a median follow-up of 53 (range, 33-61) weeks, recipients' marrow function was normal, and blood-donor chimerism levels were 97% to 100%. In summary, both autologous and allogeneic AMD3100-mobilized PBMCs led to prompt and durable engraftment in dogs after 920 cGy TBI. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Antagonizing CXCR4 accelerates CD34+ cell mobilization Steven M. Devine Blood 2005 106: 3685-3686. [Full Text] [PDF] This article has been cited by other articles: A. Zernecke, I. Bot, Y. Djalali-Talab, E. Shagdarsuren, K. Bidzhekov, S. Meiler, R. Krohn, A. Schober, M. Sperandio, O. Soehnlein, et al. Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis Circ. Res., February 1, 2008; 102(2): 209 - 217. [Abstract] [Full Text] [PDF] M. Abraham, K. Biyder, M. Begin, H. Wald, I. D. Weiss, E. Galun, A. Nagler, and A. Peled Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F-Benzoyl-TN14003 Stem Cells, September 1, 2007; 25(9): 2158 - 2166. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020